These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25426290)

  • 21. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.
    Stevens V; Dumyati G; Brown J; Wijngaarden E
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection.
    Cao F; Chen CX; Wang M; Liao HR; Wang MX; Hua SZ; Huang B; Xiong Y; Zhang JY; Xu YL
    J Hosp Infect; 2018 Jan; 98(1):4-13. PubMed ID: 28842261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional differences in Clostridium difficile infections in relation to fluoroquinolone and proton pump inhibitor use, Finland, 2008-2011.
    Kanerva M; Ollgren J; Voipio T; Mentula S; Lyytikäinen O
    Infect Dis (Lond); 2015 Aug; 47(8):530-5. PubMed ID: 25832317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection.
    Vincent C; Miller MA; Edens TJ; Mehrotra S; Dewar K; Manges AR
    Microbiome; 2016 Mar; 4():12. PubMed ID: 26975510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore.
    Koo SH; Deng J; Ang DSW; Hsiang JC; Lee LS; Aazmi S; Mohamed EHM; Yang H; Yap SY; Teh LK; Salleh MZ; Lee EJD; Ang TL
    Singapore Med J; 2019 Oct; 60(10):512-521. PubMed ID: 30488079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evaluation of Clostridium difficile infection (CDI) in a community hospital.
    Daniel A; Rapose A
    J Infect Public Health; 2015; 8(2):155-60. PubMed ID: 25301221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and management of Clostridium difficile infection.
    Dupont HL
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1216-23; quiz e73. PubMed ID: 23542332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes.
    Weitsman S; Celly S; Leite G; Mathur R; Sedighi R; Barlow GM; Morales W; Sanchez M; Parodi G; Villanueva-Millan MJ; Rezaie A; Pimentel M
    Dig Dis Sci; 2022 Jan; 67(1):224-232. PubMed ID: 33534012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.
    Kurti Z; Lovasz BD; Mandel MD; Csima Z; Golovics PA; Csako BD; Mohas A; Gönczi L; Gecse KB; Kiss LS; Szathmari M; Lakatos PL
    World J Gastroenterol; 2015 Jun; 21(21):6728-35. PubMed ID: 26074711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of proton pump inhibitors in infants with esophageal atresia on the gut microbiome: a pilot cohort.
    Brusselaers N; Pereira M; Alm J; Engstrand L; Engstrand Lilja H
    Gut Pathog; 2022 Dec; 14(1):47. PubMed ID: 36527125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacterial and Fungal Microbiota Changes Distinguish C. difficile Infection from Other Forms of Diarrhea: Results of a Prospective Inpatient Study.
    Sangster W; Hegarty JP; Schieffer KM; Wright JR; Hackman J; Toole DR; Lamendella R; Stewart DB
    Front Microbiol; 2016; 7():789. PubMed ID: 27252696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors.
    Saruta Y; Watanabe K; Tsuji T; Takahashi Y; Matsuzawa H; Yoshida T; Takahashi S; Shimodaira Y; Matsuhashi T; Iijima K
    J Gastroenterol Hepatol; 2023 Jun; 38(6):940-947. PubMed ID: 36882162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proton pump inhibitors and 180-day mortality in the elderly after
    Bradley ES; Howe E; Wu X; Haran JP
    Gut Pathog; 2019; 11():29. PubMed ID: 31210787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis.
    D'Silva KM; Mehta R; Mitchell M; Lee TC; Singhal V; Wilson MG; McDonald EG
    Clin Microbiol Infect; 2021 Jan; ():. PubMed ID: 33465501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimorbidity in elderly hospitalised patients and risk of Clostridium difficile infection: a retrospective study with the Cumulative Illness Rating Scale (CIRS).
    Ticinesi A; Nouvenne A; Folesani G; Prati B; Morelli I; Guida L; Turroni F; Ventura M; Lauretani F; Maggio M; Meschi T
    BMJ Open; 2015 Oct; 5(10):e009316. PubMed ID: 26503394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors.
    Hojo M; Asahara T; Nagahara A; Takeda T; Matsumoto K; Ueyama H; Matsumoto K; Asaoka D; Takahashi T; Nomoto K; Yamashiro Y; Watanabe S
    Dig Dis Sci; 2018 Nov; 63(11):2940-2949. PubMed ID: 29796911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clostridium difficile: improving the prevention paradigm in healthcare settings.
    Vassallo A; Tran MC; Goldstein EJ
    Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1087-102. PubMed ID: 25109301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011.
    Chitnis AS; Holzbauer SM; Belflower RM; Winston LG; Bamberg WM; Lyons C; Farley MM; Dumyati GK; Wilson LE; Beldavs ZG; Dunn JR; Gould LH; MacCannell DR; Gerding DN; McDonald LC; Lessa FC
    JAMA Intern Med; 2013 Jul; 173(14):1359-67. PubMed ID: 23780507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection.
    Tawam D; Baladi M; Jungsuwadee P; Earl G; Han J
    Innov Pharm; 2021; 12(1):. PubMed ID: 34007671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy.
    King RN; Lager SL
    Pharmacotherapy; 2011 Jul; 31(7):642-8. PubMed ID: 21923450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.